Selectivity and Long Action of In Vivo Efficacy of CS585, a Novel Prostacyclin Receptor Agonist, Compared to FDA-Approved Prostacyclin Agonists Iloprost and Selexipag in the Prevention of Thrombosis

Uptravi (selexipag) - J&J

CS585 - Cereno Scientific

Ventavis (iloprost) - Bayer, J&J, University of Copenhagen

Livia Stanger1; Mariane Flores, PhD1; Krista A Goerger, BSc1; Bjorn Dahlof, MD, PhD2; Michael Holinstat, PhD1

Nov 6, 2024